Literature DB >> 6091536

Comparative pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime in rats, dogs, and rhesus monkeys.

H Matsui, M Komiya, C Ikeda, A Tachibana.   

Abstract

The pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime were studied in rats, dogs, and rhesus monkeys (only YM-13115 and ceftriaxone were studied in rhesus monkeys). The plasma half-lives in rats were 48 min for YM-13115, 34 min for ceftriaxone, and 14 min for ceftazidime. In dogs, they were 21.9 min for YM-13115, 50.7 min for ceftriaxone, and 49.0 min for ceftazidime. In monkeys, they were 5.30 h for YM-13115 and 3.40 h for ceftriaxone. The 24-h urinary recoveries in rats were 26.7% of the dose for YM-13115, 32.0% for ceftriaxone, and 97.1% for ceftazidime. In dogs, they were 13.3% for YM-13115, 62.5% for ceftriaxone, and 86.3% for ceftazidime. In monkeys, they were 22.5% for YM-13115 and 29.3% for ceftriaxone. The 24-h biliary recoveries in rats were 72.2% for YM-13115, 61.8% for ceftriaxone, and 0.63% for ceftazidime.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6091536      PMCID: PMC284120          DOI: 10.1128/AAC.26.2.204

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Concept of a volume of distribution and possible errors in evaluation of this parameter.

Authors:  S Riegelman; J Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

2.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

3.  Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin.

Authors:  R Reiner; U Weiss; U Brombacher; P Lanz; M Montavon; A Furlenmeier; P Angehrn; P J Probst
Journal:  J Antibiot (Tokyo)       Date:  1980-07       Impact factor: 2.649

4.  Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys.

Authors:  H Matsui; K Yano; T Okuda
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

5.  Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals.

Authors:  M Komiya; Y Kikuchi; A Tachibana; K Yano
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

6.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

7.  Pharmacokinetics of cefpiramide (SM-1652) in humans.

Authors:  K Nakagawa; M Koyama; H Matsui; C Ikeda; K Yano; N Nakatsuru; K Yoshinaga; T Noguchi
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

8.  Pharmacokinetics of cefotetan (YM09330) in humans.

Authors:  K Nakagawa; M Koyama; A Tachibana; M Komiya; Y Kikuchi; K Yano
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

  8 in total
  8 in total

1.  Comparison of the Pharmacokinetic Profiles of Ceftriaxone Used Alone and Combined with Danhong Injection in Old Rats.

Authors:  Qian Zhang; Jianming Guo; Guoliang Dai; Jianping Li; Lijing Zhu; Shufen He; Yang Zong; Zhishu Tang; Buchang Zhao; Wenzheng Ju; Jinao Duan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-08       Impact factor: 2.441

Review 2.  Critical analysis of treatment trials of rhesus macaques infected with Borrelia burgdorferi reveals important flaws in experimental design.

Authors:  Gary P Wormser; Phillip J Baker; Susan O'Connell; Andrew R Pachner; Ira Schwartz; Eugene D Shapiro
Journal:  Vector Borne Zoonotic Dis       Date:  2012-05-23       Impact factor: 2.133

3.  The pharmacokinetics of ceftazidime in lactating and non-lactating cows.

Authors:  R Rule; G H Quiroga; M Rubio; H O Buschiazzo; P M Buschiazzo
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

4.  In vitro studies on the antibacterial activities of YM-13115, a new broad-spectrum cephalosporin.

Authors:  M Toda; N Arao; C Nohara; K Susaki; A Tachibana
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

Review 5.  Characterizing ceftriaxone-induced urolithiasis and its associated acute kidney injury: an animal study and Chinese clinical systematic review.

Authors:  Yifan Zhang; Benxiang Ning; Huaijun Zhu; Xiaoming Cong; Leqing Zhou; Qiang Wang; Liming Zhang; Xizhao Sun
Journal:  Int Urol Nephrol       Date:  2016-04-28       Impact factor: 2.370

6.  Daily variations in ceftriaxone pharmacokinetics in rats.

Authors:  M Rebuelto; L Ambros; M Rubio
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

7.  Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys.

Authors:  S T Forgue; W C Shyu; C R Gleason; K A Pittman; R H Barbhaiya
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

8.  Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection.

Authors:  Monica E Embers; Stephen W Barthold; Juan T Borda; Lisa Bowers; Lara Doyle; Emir Hodzic; Mary B Jacobs; Nicole R Hasenkampf; Dale S Martin; Sukanya Narasimhan; Kathrine M Phillippi-Falkenstein; Jeanette E Purcell; Marion S Ratterree; Mario T Philipp
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.